(ADMA) ADMA Biologics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.917m USD | Total Return: -58% in 12m

Immune Globulin, Polyclonal Antibodies, Human Plasma
Total Rating 39
Safety 92
Buy Signal -0.64
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.92B
Avg Turnover: 46.3M
Risk 3d forecast
Volatility51.6%
VaR 5th Pctl8.42%
VaR vs Median-0.93%
Reward TTM
Sharpe Ratio-1.38
Rel. Str. IBD0.4
Rel. Str. Peer Group0.3
Character TTM
Beta1.191
Beta Downside0.479
Hurst Exponent0.563
Drawdowns 3y
Max DD67.85%
CAGR/Max DD0.43
CAGR/Mean DD1.56
EPS (Earnings per Share) EPS (Earnings per Share) of ADMA over the last years for every Quarter: "2021-03": -0.16, "2021-06": -0.14, "2021-09": -0.13, "2021-12": -0.09, "2022-03": -0.1, "2022-06": -0.07, "2022-09": -0.08, "2022-12": -0.06, "2023-03": -0.03, "2023-06": -0.03, "2023-09": 0.01, "2023-12": -0.08, "2024-03": 0.08, "2024-06": 0.13, "2024-09": 0.15, "2024-12": 0.136, "2025-03": 0.11, "2025-06": 0.14, "2025-09": 0.15, "2025-12": 0.2157, "2026-03": 0.1695,
Last SUE: -1.12
Qual. Beats: -1
Revenue Revenue of ADMA over the last years for every Quarter: 2021-03: 16.048618, 2021-06: 17.83059, 2021-09: 20.68055, 2021-12: 26.382867, 2022-03: 29.103093, 2022-06: 33.905007, 2022-09: 41.090137, 2022-12: 49.981455, 2023-03: 56.914, 2023-06: 60.123, 2023-09: 67.275, 2023-12: 73.903677, 2024-03: 81.875, 2024-06: 107.191, 2024-09: 119.839, 2024-12: 117.549, 2025-03: 114.802, 2025-06: 121.984, 2025-09: 134.224, 2025-12: 139.163, 2026-03: 114.493,
Rev. CAGR: 41.86%
Rev. Trend: 96.9%
Last SUE: -4.00
Qual. Beats: -1

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: ADMA ADMA Biologics

ADMA Biologics is a vertically integrated biopharmaceutical company specializing in the development and commercialization of plasma-derived biologics. The company manages the full lifecycle of its products, from the operation of source plasma collection centers to the manufacturing and distribution of specialty treatments for primary humoral immunodeficiency and infectious diseases.

The company’s commercial portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies, and Nabi-HB for Hepatitis B exposure. This business model relies on a complex fractionating process to extract specific antibodies from human plasma, a sector characterized by high barriers to entry and rigorous regulatory oversight due to the biological nature of the raw materials.

ADMA distributes its therapeutics through a network of wholesalers, specialty pharmacies, and independent distributors. Investors may find additional performance metrics and peer comparisons by exploring ValueRay. Headquartered in New Jersey, the firm continues to develop a pipeline focused on preventing Streptococcus pneumoniae infections using its proprietary plasma-derived platform.

Headlines to Watch Out For
  • ASCENIV adoption and utilization rates drive high-margin revenue growth
  • Vertical integration of plasma collection centers stabilizes raw material costs
  • FDA regulatory compliance at manufacturing facilities ensures uninterrupted product supply
  • Expansion of intravenous immune globulin market share increases total revenue
  • Operational leverage improvement accelerates transition toward sustained net profitability
Piotroski VR‑10 (Strict) 4.5
Net Income: 165.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.16 > 0.02 and ΔFCF/TA -1.53 > 1.0
NWC/Revenue: 85.83% < 20% (prev 64.94%; Δ 20.89% < -1%)
CFO/TA 0.19 > 3% & CFO 128.3m > Net Income 165.4m
Net Debt (74.0m) to EBITDA (212.6m): 0.35 < 3
Current Ratio: 6.95 > 1.5 & < 3
Outstanding Shares: last quarter (240.0m) vs 12m ago -1.93% < -2%
Gross Margin: 61.27% > 18% (prev 0.53%; Δ 6.07k% > 0.5%)
Asset Turnover: 86.73% > 50% (prev 89.97%; Δ -3.24% > 0%)
Interest Coverage Ratio: 28.28 > 6 (EBITDA TTM 212.6m / Interest Expense TTM 7.24m)
Altman Z'' 5.64
A: 0.66 (Total Current Assets 511.2m - Total Current Liabilities 73.5m) / Total Assets 665.2m
B: -0.17 (Retained Earnings -116.3m / Total Assets 665.2m)
C: 0.35 (EBIT TTM 204.6m / Avg Total Assets 587.9m)
D: -0.42 (Book Value of Equity -116.3m / Total Liabilities 274.9m)
Altman-Z'' = 5.64 = AAA
Beneish M -3.02
DSRI: 1.23 (Receivables 135.9m/99.4m, Revenue 509.9m/459.4m)
GMI: 0.86 (GM 61.27% / 52.58%)
AQI: 0.68 (AQ_t 0.12 / AQ_t-1 0.18)
SGI: 1.11 (Revenue 509.9m / 459.4m)
TATA: 0.06 (NI 165.4m - CFO 128.3m) / TA 665.2m)
Beneish M = -3.02 (Cap -4..+1) = AA
What is the price of ADMA shares? As of May 23, 2026, the stock is trading at USD 8.46 with a total of 3,291,383 shares traded.
Over the past week, the price has changed by -0.47%, over one month by -21.52%, over three months by -48.07% and over the past year by -57.95%.
Is ADMA a buy, sell or hold? ADMA Biologics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ADMA.
  • StrongBuy: 2
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ADMA price?
Analysts Target Price 16.8 98%
ADMA Biologics (ADMA) - Fundamental Data Overview as of 17 May 2026
P/E Trailing = 12.1618
P/E Forward = 9.8425
P/S = 3.7594
P/B = 4.8513
Revenue TTM = 509.9m USD
EBIT TTM = 204.6m USD
EBITDA TTM = 212.6m USD
Long Term Debt = 69.3m USD (from longTermDebt, last fiscal year)
Short Term Debt = 4.46m USD (from shortTermDebt, last quarter)
Debt = 212.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.74m
Net Debt = 74.0m USD (calculated: Debt 212.1m - CCE 138.2m)
Enterprise Value = 1.99b USD (1.92b + Debt 212.1m - CCE 138.2m)
Interest Coverage Ratio = 28.28 (Ebit TTM 204.6m / Interest Expense TTM 7.24m)
EV/FCF = 18.45x (Enterprise Value 1.99b / FCF TTM 107.9m)
FCF Yield = 5.42% (FCF TTM 107.9m / Enterprise Value 1.99b)
FCF Margin = 21.16% (FCF TTM 107.9m / Revenue TTM 509.9m)
Net Margin = 32.43% (Net Income TTM 165.4m / Revenue TTM 509.9m)
Gross Margin = 61.27% ((Revenue TTM 509.9m - Cost of Revenue TTM 197.4m) / Revenue TTM)
Gross Margin QoQ = 70.53% (prev 63.82%)
Tobins Q-Ratio = 2.99 (Enterprise Value 1.99b / Total Assets 665.2m)
Interest Expense / Debt = 0.99% (Interest Expense 2.10m / Debt 212.1m)
Taxrate = 20.65% (11.8m / 57.1m)
NOPAT = 162.4m (EBIT 204.6m * (1 - 20.65%))
Current Ratio = 6.95 (Total Current Assets 511.2m / Total Current Liabilities 73.5m)
Debt / Equity = 0.54 (Debt 212.1m / totalStockholderEquity, last quarter 390.3m)
Debt / EBITDA = 0.35 (Net Debt 74.0m / EBITDA 212.6m)
Debt / FCF = 0.69 (Net Debt 74.0m / FCF TTM 107.9m)
Total Stockholder Equity = 424.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 28.13% (Net Income 165.4m / Total Assets 665.2m)
RoE = 30.59% (Net Income TTM 165.4m / Total Stockholder Equity 540.6m)
RoCE = 33.55% (EBIT 204.6m / Capital Employed (Equity 540.6m + L.T.Debt 69.3m))
RoIC = 35.46% (NOPAT 162.4m / Invested Capital 457.9m)
WACC = 9.23% (E(1.92b)/V(2.13b) * Re(10.17%) + D(212.1m)/V(2.13b) * Rd(0.99%) * (1-Tc(0.21)))
Discount Rate = 10.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 20.0 | Cagr: 2.71%
[DCF] Terminal Value 65.26% ; FCFF base≈101.0m ; Y1≈66.3m ; Y5≈30.3m
[DCF] Fair Price = 1.81 (EV 493.6m - Net Debt 74.0m = Equity 419.6m / Shares 231.8m; r=9.23% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.12 | # QB: -1
Revenue Correlation: 96.93 | Revenue CAGR: 41.86% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.18 | Chg30d=-28.00% | Revisions=-20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.21 | Chg30d=-25.00% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=0.83 | Chg30d=-20.19% | Revisions=-20% | GrowthEPS=+26.4% | GrowthRev=+11.7%
EPS next Year (2027-12-31): EPS=1.06 | Chg30d=-14.78% | Revisions=-20% | GrowthEPS=+27.3% | GrowthRev=+27.4%
[Analyst] Revisions Ratio: -20%